Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;34(2):213-238.
doi: 10.1007/s00198-022-06523-7. Epub 2022 Aug 18.

Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders

Francesca Marini  1 , Francesca Giusti  2   3 , Gaia Palmini  3 , Maria Luisa Brandi  4   5
Affiliations
Review

Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders

Francesca Marini et al. Osteoporos Int. 2023 Feb.

Abstract

Wnt signaling and its bone tissue-specific inhibitor sclerostin are key regulators of bone homeostasis. The therapeutic potential of anti-sclerostin antibodies (Scl-Abs), for bone mass recovery and fragility fracture prevention in low bone mass phenotypes, has been supported by animal studies. The Scl-Ab romosozumab is currently used for osteoporosis treatment.

Introduction: Wnt signaling is a key regulator of skeletal development and homeostasis; germinal mutations affecting genes encoding components, inhibitors, and enhancers of the Wnt pathways were shown to be responsible for the development of rare congenital metabolic bone disorders. Sclerostin is a bone tissue-specific inhibitor of the Wnt/β-catenin pathway, secreted by osteocytes, negatively regulating osteogenic differentiation and bone formation, and promoting osteoclastogenesis and bone resorption.

Purpose and methods: Here, we reviewed current knowledge on the role of sclerostin and Wnt pathways in bone metabolism and skeletal disorders, and on the state of the art of therapy with sclerostin-neutralizing antibodies in low-bone-mass diseases.

Results: Various in vivo studies on animal models of human low-bone-mass diseases showed that targeting sclerostin to recover bone mass, restore bone strength, and prevent fragility fracture was safe and effective in osteoporosis, osteogenesis imperfecta, and osteoporosis pseudoglioma. Currently, only treatment with romosozumab, a humanized monoclonal anti-sclerostin antibody, has been approved in human clinical practice for the treatment of osteoporosis, showing a valuable capability to increase BMD at various skeletal sites and reduce the occurrence of new vertebral, non-vertebral, and hip fragility fractures in treated male and female osteoporotic patients.

Conclusions: Preclinical studies demonstrated safety and efficacy of therapy with anti-sclerostin monoclonal antibodies in the preservation/restoration of bone mass and prevention of fragility fractures in low-bone-mass clinical phenotypes, other than osteoporosis, to be validated by clinical studies for their approved translation into prevalent clinical practice.

Keywords: Lipoprotein receptor–related protein 5 (LPR5); SOST gene; Sclerostin; Wnt proteins; Wnt signaling pathway; β-Catenin.

PubMed Disclaimer

References

    1. Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A, Lee E (2013) The way Wnt works: components and mechanism. Growth Factors 31(1):1–31. https://doi.org/10.3109/08977 - DOI
    1. Chen C, Zhao M, Tian A, Zhang X, Yao Z, Ma X (2015) Aberrant activation of Wntbeta-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget 6(19):17570–83. https://doi.org/10.18632/oncotarget.4100.194.2012.752737 - DOI
    1. Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, Kayama T, Saito M, Marumo K (2019) The regulation of bone metabolism and disorders by Wnt signaling. Int J Mol Sci 20(22):5525. https://doi.org/10.3390/ijms20225525 - DOI
    1. Duan P, Bonewald LF (2016) The role of the wnt/beta-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol 77(PtA):23–29. https://doi.org/10.1016/j.biocel.2016.05.015 - DOI
    1. Jiang X, Charlat O, Zamponi R, Yang Y, Cong F (2015) Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases. Mol Cell 58(3):522–533. https://doi.org/10.1016/j.molcel.2015.03.015 - DOI

Substances